Home » Stocks » Entasis Therapeutics

Entasis Therapeutics Holdings Inc. (ETTX)

Stock Price: $2.92 USD -0.03 (-1.02%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 42.67M
Revenue (ttm) 7.00M
Net Income (ttm) -46.18M
Shares Out 27.29M
EPS (ttm) -3.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $2.92
Previous Close $2.95
Change ($) -0.03
Change (%) -1.02%
Day's Open 2.95
Day's Range 2.84 - 3.05
Day's Volume 243,889
52-Week Range 1.75 - 9.25

More Stats

Market Cap 42.67M
Enterprise Value 16.38M
Earnings Date (est) Aug 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 27.29M
Float 3.89M
EPS (basic) -3.5
EPS (diluted) -3.50
FCF / Share -3.60
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 24,124
Short Ratio 0.41
Short % of Float 0.12%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 6.10
PB Ratio 2.91
Revenue 7.00M
Operating Income -48.15M
Net Income -46.18M
Free Cash Flow -47.78M
Net Cash 26.29M
Net Cash / Share 1.80
Gross Margin 100.00%
Operating Margin -687.83%
Profit Margin -659.60%
FCF Margin -682.57%
ROA -51.92%
ROE -93.97%
ROIC -130.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$6.25*
(114.04% upside)
Low
5.00
Current: 2.92
High
8.00
Target: 6.25
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016
Revenue7.005.00--
Revenue Growth40%---
Gross Profit7.005.00--
Operating Income-46.94-38.21-31.34-19.10
Net Income-43.85-42.09-29.92-19.10
Shares Outstanding13.163.42-0.10
Earnings Per Share-3.33-12.31-13,795.76-190,950.00
Operating Cash Flow-44.74-35.82-27.16-15.95
Capital Expenditures-0.11-0.37-0.29-0.14
Free Cash Flow-44.85-36.19-27.45-16.09
Cash & Equivalents41.0085.0955.1026.26
Total Debt1.32---
Net Cash / Debt39.6885.0955.1026.26
Assets51.0389.2758.7927.07
Liabilities8.886.399.875.00
Book Value42.1682.88-55.79-26.34
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Entasis Therapeutics Holdings Inc.
Country United States
Employees 48
CEO Manoussos Perros

Stock Information

Ticker Symbol ETTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ETTX
IPO Date September 26, 2018

Description

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. It is involved in developing Sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that has completed Phase II clinical trial for the treatment of multi-drug resistant Acinetobacter infections; Zoliflodacin, a novel orally administered molecule that has completed Phase II clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant Gram-negative infections. The company has collaboration agreements with Zai Lab (Shanghai) Co., Ltd. for developing SUL-DUR. Entasis Therapeutics Holdings Inc. was incorporated in 2018 and is based in Waltham, Massachusetts.